Clinical Trials

Infection Risk: CAR T-Cell vs. Bispecific Antibodies?
Research & Development Infection Risk: CAR T-Cell vs. Bispecific Antibodies?

Unlike the single-infusion protocol of CAR T-cells, the repeated administration of bispecific antibodies may prevent the immune system from achieving full recovery. This observation has become central to oncological discussions in 2026 as these advanced immunotherapies dominate the treatment

Anthracyclines May Not Be Needed for Early-Stage TNBC Treatment
Research & Development Anthracyclines May Not Be Needed for Early-Stage TNBC Treatment

Oncologists are increasingly diverging from official national guidelines to prioritize de-escalation strategies that maintain efficacy while reducing the severe drug burden on the body. Triple-negative breast cancer (TNBC) has long been regarded as one of the most daunting subtypes of the disease

Can Vitamin C Prevent the Progression of Blood Cancer?
Management & Regulatory Can Vitamin C Prevent the Progression of Blood Cancer?

The historical paradigm of hematological care is undergoing a fundamental transformation as researchers move beyond traditional cytotoxic treatments toward the strategic use of nutrient-based epigenetic modulators to intercept cancer in its earliest stages. This shift marks a move from reactive,

Can a New Gene Therapy Restore Vision in XLRP Patients?
Research & Development Can a New Gene Therapy Restore Vision in XLRP Patients?

For decades, the diagnosis of X-linked retinitis pigmentosa has functioned as a slow-motion countdown toward permanent darkness, leaving thousands of young men to watch their peripheral and night vision slowly fade away without any realistic hope for medical intervention. This devastating genetic

Evaluating GLP-1 Risks in Body Contouring Surgery Safety
Tech & Innovation Evaluating GLP-1 Risks in Body Contouring Surgery Safety

Evidence-based medicine in the field of plastic surgery is evolving to address the specific needs of a patient demographic redefined by blockbuster weight-loss drugs. The widespread adoption of glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide and tirzepatide, has created a

Symbolic Neural Generation Advances Lead Discovery in Drug Design
Tech & Innovation Symbolic Neural Generation Advances Lead Discovery in Drug Design

By leveraging a system of base and fibre posets, computational chemists can now characterize the search space for new drugs with mathematical precision and formal semantics. The pharmaceutical industry is currently witnessing a significant shift as artificial intelligence moves from being an

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later